Aclara and Illumina Report Higher Q1 Revenues, Widening Net Losses | GenomeWeb

NEW YORK, April 26 - Early-stage assay makers Aclara Biosciences and Illumina both reported slightly higher revenues for the first quarter of 2001, coupled with rises in net losses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.